2012, Number 1
<< Back Next >>
Rev Med Inst Mex Seguro Soc 2012; 50 (1)
Costs of breast cancer treatment prior to the introduction of immunebased therapy in México
Meneses-García A, Ramírez T, Ruiz-Godoy L, Chiquete E, Mohar A
Language: Spanish
References: 20
Page: 19-24
PDF size: 43.58 Kb.
ABSTRACT
Background: the aim was to perform a cost analysis on direct
data of integral medical care provided to BC patients prior to
introduction of immunotherapy.
Methods: a total of 633 patients were studied. Direct costs calculations
were performed on individual patient data in a subset of 309
randomly selected patients, extrapolating calculations to the universe
of 633 patients. Information was obtained for each management
process (diagnosis and staging, cancer management, symptoms
control, palliative care and follow-up). Costs are expressed in 2008
US dollars (USD) and adjusted to a 3 % discount rate.
Results: the clinical stage distribution in the 633 patients was 41,
191, 240 and 58 patients for clinical stages I to IV, respectively;
with 103 patients referred from other institutions without staging.
The annual costs of care per patient was, in clinical stage I: 6,219,94
USD; stage II: 7,498.04 USD; stage III: 9,610.31 USD; stage IV:
9,917.82 USD; and in patients without staging: 7,504.41 USD.
The exact total integral cost according to the universe of BC patients
(
n = 633) by 2004 was 5,341,805.37 USD.
Conclusions: before the introduction of immune-based therapy costs
of care for Mexican women with BC increased with advanced stages
do to a significant proportion of patients were diagnosed late.
REFERENCES
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108.
García M, Jemal A, Ward E, Center M, Hao Y, Siegel R, et al. Global cancer facts and figures 2007. Estimated number of new cancer cases by World Area, 2007. Atlanta. USA: American Cancer Society; 2007. p. 1-46.
Dirección General de Epidemiología. Registro histopatológico de neoplasias malignas 2001. Disponible en http://www. dgepi.salud.gob.mx/diveent/RHNM.htm
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-2917.
Anderson BO, Shyyan R, Eniu A, Smith RA, Chow LW, Masiid S, et al. Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J 2006;12(Suppl 1):S3-S15.
Mohar A, Bargalló E, Ramírez MT, Lara F, Beltrán-Ortega A. Recursos disponibles para el tratamiento del cáncer de mama en México. Salud Publica Mex 2009;51 (Suppl 2):s263-s269. Disponible en http://www.scielosp. org/scielo.php?pid=S003636342009000800017&script= sci_arttext
Romero-Figueroa M, Santillán-Arreygue L, Miranda-García M, Torres-Arreola L, Pérez-Espejel IM, Duarte-Mote J, et al. Patrón epidemiológico de la mortalidad por cáncer de mama en el Estado de México. Rev Med Inst Mex Seguro Soc 2010;48:253-258.
Aguayo-Alcaraz G, Jiménez-Pérez LM, Celis-de la Rosa A, Canales-Muñoz JL. Mortalidad por cáncer de mama. Tendencia y distribución geográfica, 1981-2001. Rev Med Inst Mex Seguro Soc 2008;46(4):367-374.
Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. New York: Oxford University Press; 2007.
Lazcano-Ponce E, Allen-Leigh B. Innovation in cervical cancer prevention and control in Mexico. Arch Med Res 2009;40(6):486-492.
Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health 2001;22:91-113.
Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23(3):619-629. Disponible en http://jco.ascopubs.org/content/23/3/619.long
Hanna W, Gelmon KA. Review of the literature on HER- 2/neu testing and the role of HER-2/neu as a prognostic and predictive factor in breast cancer- update December 2000 to July 2001. Current Oncol 2002;9:S2-S17.
Piccart M, Lohrisch C, Di Leo A, Larsimont D. The predictive value of HER-2 in breast cancer. Oncology 2001;61(Suppl 2):73-82.
Loredo-Pozos G, Chiquete E, Oceguera-Villanueva A, Panduro A, Siller-López F, Ramos-Márquez ME. Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates. Med Oncol 2009;26(3): 269-275.
Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58(13):2825- 31. Errata en Cancer Res 1999;59:2020.
Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized antip185HER2/ neumonoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16(8):2659-2671.
McKeage K, Lyseng-Williamson KA. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. Pharmacoeconomics 2008;26(8):699-719.
Fernández-Suárez HG, Blum-Grynberg B, Aguilar-Villalobos EJ, Bautista-Rodríguez H. validación de un instrumento para medir calidad de vida en pacientes con cáncer de mama. Rev Med Inst Mex Seguro Soc 2010;48(2):133- 138.
Knaul FM, Arreola-Ornelas H, Velázquez E, Dorantes J, Méndez O, Ávila-Burgos L El costo de la atención médica del cáncer mamario: el caso del Instituto Mexicano del Seguro Social. Salud Publica Mex 2009;51(Suppl 2):s286- s295.
Full text